{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canagliflozin+%28JNJ-28431754%29+300+mg", "query": { "intervention": "Canagliflozin (JNJ-28431754) 300 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canagliflozin+%28JNJ-28431754%29+300+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T19:50:31.392Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01381887", "title": "A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin 300mg/Placebo", "type": "DRUG" }, { "name": "Canagliflozin 300mg/Canagliflozin 150mg", "type": "DRUG" }, { "name": "Canagliflozin 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 37, "start_date": "2011-06", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-04-22", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 5, "location_summary": "Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miramar", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381887" }, { "nct_id": "NCT00642278", "title": "An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type II", "Diabetes Mellitus, Non Insulin Dependent" ], "interventions": [ { "name": "Canagliflozin (JNJ-28431754)", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 451, "start_date": "2008-04", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Lincoln", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642278" }, { "nct_id": "NCT01186588", "title": "A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Hepatic Insufficiency" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2010-08", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2013-05-29", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 2, "location_summary": "Orlando, Florida • Knoxville, Tennessee", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186588" }, { "nct_id": "NCT02025907", "title": "A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 218, "start_date": "2014-02", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 30, "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Northridge", "state": "California" }, { "city": "Norwalk", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02025907" }, { "nct_id": "NCT02009488", "title": "Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2014-09-08", "completion_date": "2017-01-03", "has_results": false, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 2, "location_summary": "San Diego, La Jolla, California • Gainesville, Florida", "locations": [ { "city": "San Diego, La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009488" }, { "nct_id": "NCT01939496", "title": "Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2", "Hypertension" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 171, "start_date": "2013-10", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01939496" }, { "nct_id": "NCT01508182", "title": "A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin tablets", "type": "DRUG" }, { "name": "Metformin IR tablets", "type": "DRUG" }, { "name": "Canagliflozin/metformin IR FDC tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2012-01", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508182" }, { "nct_id": "NCT00963768", "title": "A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "JNJ 28431754", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 116, "start_date": "2007-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963768" }, { "nct_id": "NCT02000700", "title": "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 50 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 17, "start_date": "2014-03", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000700" }, { "nct_id": "NCT01809327", "title": "A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1186, "start_date": "2013-06-04", "completion_date": "2014-12-02", "has_results": true, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-10-08T19:50:31.392Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01809327" } ] }